All Phenotypes Tcf21<tm2.1Seq> MGI Mouse

• significantly increased urinary protein to creatinine ratio in affected mice

• streptozotocin induced diabetes at 17 weeks of age in protected cohort results in increased urinary protein to creatinine ratio

increased urine protein level ( J:217144 )

• massive proteinuria in 40% of mice by 5 weeks of age

• 60& of mice do not develop proteinuria through 8 months of age

• in protected cohort of mice proteinuria development resumes after 32 weeks of age

• streptozotocin induced diabetes at 17 weeks of age in protected cohort results in massive proteinuria

abnormal kidney morphology ( J:217144 )

• dynamic proliferation of cells in Bowman's capsule

abnormal podocyte morphology ( J:217144 )

• occasional podocyte vacuolation

• focal flattening and disorganized foot processes in all mice

podocyte foot process effacement ( J:217144 )

• extensive effacement in affected mice with large bumpy subepithelial protrusions of the glomerular basement membrane

• prominent fibrinogen depositions

• simplified glomerular structure at birth and at 3 weeks of age

• total cell number reduced by 15%

• non-podocyte cell number reduced 25%

glomerulosclerosis ( J:217144 )

• focal and segmental glomerulosclerosis with occasional crescent formation and podocyte vacuolation

• streptozotocin induced diabetes at 17 weeks of age in protected cohort results in dramatic glomerulosclerosis

kidney atrophy ( J:217144 )

• with an irregular surface in affected mice

pale kidney ( J:217144 )

• in affected mice

abnormal kidney physiology ( J:217144 )

• end stage renal disease in some mice with death at 3-6 weeks of age

abnormal urine homeostasis ( J:217144 )